Monday, 25 May 2020 | 12:34 WIB

Researchers from US and China Begin Covid-19 Vaccine Trials on Humans

Researchers from US and China Begin Covid-19 Vaccine Trials on Humans (guardian)

JAKARTA, NETRALNEWS.COM - Researchers from the United States and China have began testing the Covid-19 coronavirus  vaccine on humans.

In China, researchers at the Military Medical Academy have received approval to launch an early-stage clinical trial of the SARS-CoV-2 coronavirus vaccine that caused Covid-19. The vaccine, which has the potential to cure the virud,, is tested this week.

According to the clinical trial registration database in China, Phase I tests will evaluate the safety of experimental trials in humans. A total of 108 people who were not infected with Covid-19 in the span of 31 December 2019 and 16 March 2020 are assigned as part of the experimental trials.

As reported by Daily Mail, chief vaccine researcher Chen Wei said Beijing had given permission to start the test. The research team has also prepared vaccine production on a large scale.

"The vaccine is the strongest scientific weapon to end the coronavirus," said Chen, who is a two-star military officer in the Chinese armed forces.

"If China is the first country to create such a weapon and has its own patent, it shows the progress of our science and the country's image," he said.

The Covid-19 vaccine recombination was successfully developed by Chen after more than one month of research. Chen, a leading specialist in genetic engineering vaccines in China, was also known to develop medical sprays during the SARS outbreak in 2003. The product prevented about 14,000 medical workers from contracting the virus.

Chen is also known as the 'Ebola terminator' for leading a team to make a vaccine against the fatal disease.

Meanwhile, the United States is also conducting phase I testing of the Moderna mRNA vaccine (mRNA-1273). In addition,  the National Institute of Health (NIH) is conducting trials under its own application of investigational new drugs (IND).

The Phase I Study will involve 45 healthy adults to evaluate the safety and immunogenicity of the 25μg, 100μg, 250μg dose mRNA-1273 dose given on the vaccination schedule by two doses.

On the one hand, a number of World Health Organization experts say that they are not sure the vaccine is really effective and can be found until the middle of next year. At present, they are considered to only take steps to prevent the spread of the coronavirus.